Skip to main content
RHAPSIDO® (remibrutinib) 25mg tablets. NOW APPROVED. Patient portrayal.

RHAPSIDO: a first-of-its-kind* oral targeted therapy for CSU1

When antihistamines aren't enough for chronic spontaneous urticaria (CSU), cut to RHAPSIDO. It is not indicated for other forms of urticaria1

Relief in a pill

After trying antihistamines, treat CSU while keeping your patients on an oral regimen.1

$0 Co-Pay Plus offer

We help make treatments more affordable for your eligible patients through our Co-Pay Plus offer.

*Bruton's tyrosine kinase inhibitor indicated for CSU.1
Multiple imputation techniques were implemented for missing data.1
Limitations apply. Subject to annual co-pay benefit limit. Offer not valid under Medicare, Medicaid, or any other federal or state programs. Novartis reserves the right to rescind, revoke, or amend this program without notice. Additional limitations may apply. See complete Terms & Conditions at rhapsido.com for details.
CFB, change from baseline; HSS7, Weekly Hives Severity Score; ISS7, Weekly Itch Severity Score; LS, least squares; UAS7, Weekly Urticaria Activity Score.
 
References: 1. Rhapsido. Prescribing information. Novartis Pharmaceuticals Corp. 2. Data on file. CSR Study No. CLOU064A2302. Novartis Pharmaceuticals Corp; June 2024.